The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance

Psychopharmacology

Volumn 200, Issue 2, 2008, Pages 197-203

  Feifel, David ^a   Melendez, Gilia ^a   Murray, Rachel J ^a   Tina Tran, Dan N ^a   Rullan, Michelle A ^a   Shilling, Paul D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic; Locomotor activity; Neurotensin; NT69L; PD148163; Tolerance

Indexed keywords

AMPHETAMINE; NEUROTENSIN 1 RECEPTOR; NEUROTENSIN 2 RECEPTOR; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR; NEUROTENSIN[8-13]; PD 149163; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG TOLERANCE; INJECTIONS, SUBCUTANEOUS; MALE; MOTOR ACTIVITY; NEUROTENSIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN;

EID: 51249107114     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1197-5     Document Type: Article

References (25)

1. MP Andersen B Pouzet 2001 Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats Psychopharmacology (Berl) 156 291 304
2. M Boules P Fredrickson E Richelson 2005 Neurotensin agonists as an alternative to antipsychotics Expert Opin Investig Drugs 14 359 369
3. M Boules I Iversen A Oliveros A Shaw K Williams J Robinson P Fredrickson E Richelson 2007 The neurotensin receptor agonist NT69L suppresses sucrose-reinforced operant behavior in the rat Brain Res 1127 90 98
4. M Boules B McMahon R Wang L Warrington J Stewart S Yerbury A Fauq D McCormick E Richelson 2003 Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier Brain Res 987 39 48
5. M Boules L Warrington A Fauq D McCormick E Richelson 2001 A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity Eur J Pharmacol 426 73 76
6. GN Ervin CB Nemeroff 1988 Interactions of neurotensin with dopamine-containing neurons in the central nervous system Prog Neuro-psychopharmacol Biol Psychiatry 12 Suppl S53 S69
7. D Feifel G Melendez K Priebe PD Shilling 2007 The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats Behav Brain Res 81 278 286
8. D Feifel G Melendez PD Shilling 2003 PD149163, a neurotensin agonist, attenuates prepulse inhibition deficits produced by dizocilpine and DOI Neuropsychopharmacology 28 651 653
9. D Feifel G Melendez PD Shilling 2003 A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist Neuropsychopharmacology 28 651 653
10. D Feifel G Melendez PD Shilling 2004 Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects Neuropsychopharmacology 29 731 738
11. D Feifel KL Minor S Dulawa NR Swerdlow 1997 The effects of intra-accumbens neurotensin on sensorimotor gating Brain Res 760 80 84
12. D Feifel TL Reza DJ Wustrow MD Davis 1999 Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist J Pharmacol Exp Ther 288 710 713
13. K Fuxe G Von Euler LF Agnati E Merlo Pich WT O'Connor S Tanganelli XM Li B Tinner A Cintra C Carani 1992 Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin Ann NY Acad Sci 668 186 204
14. MK Hadden KS Orwig KP Kokko J Mazella TA Dix 2005 Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues Neuropharmacology 49 8 1149 1159
15. P Hertel L Byskov M Didriksen J Arnt 2001 Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity Eur J Pharmacol 422 77 81
16. P Hertel CK Olsen J Arnt 2002 Repeated administration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour Eur J Pharmacol 439 107 111
17. S Kapur SC VanderSpek BA Brownlee JN Nobrega 2003 Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy J Pharmacol Exp Ther 305 2 625 631
18. B Kinkead EB Binder CB Nemeroff 1999 Does neurotensin mediate the effects of antipsychotic drugs? Biol Psychiatry 46 340 351
19. B Kinkead CB Nemeroff 2004 Neurotensin, schizophrenia, and antipsychotic drug action Int Rev Neurobiol 59 327 349
20. Norman C, Beckett S, Spicer, CH, Ashton D, Langlois X, Bennett GW (2008) Effects of chronic infusion of neurotensin and neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion. J Psychopharmacol (in press). doi: 10.1177/0269881107083838
21. KA Petrie M Bubser CD Casey MD Davis BL Roth AY Deutch 2004 The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat Neuropsychopharmacology 29 1878 1888
22. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S (2008) Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry (in press). doi: 10.1016/j.biopsych.2008. 01.010
23. R Wang M Boules E Gollatz K Williams W Tiner E Richelson 2005 Effects of 5 daily injections of the neurotensin-mimetic NT69L on the expression of neurotensin receptors in rat brain Brain Res Mol Brain Res 138 24 34
24. R Wang M Boules W Tiner E Richelson 2004 Effects of repeated injections of the neurotensin analog NT69L on dopamine release and uptake in rat striatum in vitro Brain Res 1025 21 28
25. DJ Wustrow MD Davis HC Akunne AE Corbin JN Wiley LD Wise TG Heffner 1995 Reduced amide bond neurotensin 8-13 mimetics with potent in vivo activity Bioorg Med Chem Lett 5 997 1002